Advances in Clinical Chemistry

1. Auflage 2011
ISBN: 978-0-12-385856-6
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, Band Volume 53, 200 Seiten

Reihe: Advances in Clinical Chemistry

Volume 53 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology. - Leading experts from academia and clinical laboratory science - Volume emphasizes novel laboratory advances with application to clinical laboratory diagnostics and practical basic science studies

Autoren/Hrsg.

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Clinical Chemistry;4
3;Copyright Page;5
4;Contents;6
5;Contributors;10
6;Preface;14
7;Chapter 1: Use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for multiplex genotyping;16
7.1;2. Introduction;17
7.2;3. Genotyping Using Mass Spectrometry;18
7.3;4. MALDI-TOF-MS;18
7.4;5. Multiplex Genotyping by MALDI-TOF-MS;23
7.5;6. Conclusions;34
7.6;References;35
8;Chapter 2: Rheumatic heart disease: Mediation by complex immune events;46
8.1;2. Rheumatic Heart Disease;47
8.2;3. Epidemiology;47
8.3;4. Genetic Susceptibility;47
8.4;5. Immune Mechanisms Involved in RHD;54
8.5;6. Rheumatic Heart Disease Lesions;57
8.6;7. Conclusions;61
8.7;Acknowledgments;62
8.8;References;62
9;Chapter 3: Dipeptidyl peptidase in autoimmune pathophysiology;66
9.1;2. Introduction;67
9.2;3. Molecular Aspects of CD26/DPPIV Role in Immunity;68
9.3;4. Cellular Aspects of CD26/DPPIV Role in Immunity;75
9.4;5. Clinical Aspects of CD26 Role in Immune Disorders;78
9.5;6. Summary and Perspective;86
9.6;Acknowledgments;86
9.7;References;87
10;Chapter 4: Biochemistry of HELLP Syndrome;100
10.1;2. Introduction;101
10.2;3. Pathogenesis of HELLP and Preeclampsia: The Role of Placenta;104
10.3;4. Inflammatory Response in HELLP Syndrome;107
10.4;5. HELLP Syndrome, Complement Pathway, and the Coagulation System;110
10.5;6. Conclusion;113
10.6;References;113
11;Chapter 5: Homocysteine in Pregnancy;120
11.1;2. Introduction;121
11.2;3. Homocysteine Metabolism;121
11.3;4. Prophylactic Folic Acid, Folate Status, and Homocysteine;123
11.4;5. Choline and Homocysteine;124
11.5;6. Nonnutritional Factors Associated with tHcy;125
11.6;7. Health Benefits of tHcy Lowering;125
11.7;8. Pregnancy;126
11.8;Acknowledgments;144
11.9;References;144
12;Chapter 6: Diabetes and tuberculosis: Analysis of a Paradox;154
12.1;2. Introduction;155
12.2;3. Definition of the Problem;155
12.3;4. Analysis of Previous Experimental Results to Solve the Paradox;157
12.4;5. Probable Difference in Glycation Patterns of Macrophage Proteins and Its Precursors;157
12.5;6. In Silico Analysis of the Possibility of Glycation-Induced Inhibition of NADPH Oxidase;158
12.6;7. Solving the Paradox;161
12.7;Acknowledgment;165
12.8;References;165
13;Chapter 7: EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment;170
13.1;2. Introduction;1
13.2;3. The Role of Tea Polyphenols in Carcinogenesis;172
13.3;4. In Vitro and In Vivo Preclinical Studies on Tea Polyphenols;173
13.4;5. Tea Polyphenols and Their Molecular Targets in Cancer Cells;177
13.5;6. Tea Polyphenol Derivatives in Cancer Studies;181
13.6;7. Conclusions;184
13.7;Acknowledgments;185
13.8;References;185
14;Index;194